Summary of Key Points Core Viewpoint - The shareholder Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. has completed a share reduction plan, selling 1.4098 million shares of Yinos, which represents 1.00% of the total share capital, at a price range of 43.55 to 55.31 yuan per share, totaling 66.9177 million yuan [1]. Group 1 - The share reduction occurred between December 22, 2025, and January 7, 2026 [1]. - After the reduction, the shareholder holds 9.611 million shares, which is 6.82% of the total shares, down from 11.0208 million shares, or 7.82% prior to the reduction [1]. - This change in equity ownership triggered a change that touches the 1% integer multiple, indicating a significant adjustment in the shareholder's stake [1].
益诺思：股东张江生物医药基地减持1%股份